Latest & greatest articles for atorvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atorvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atorvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atorvastatin

81. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) Smith D G, McBurney C R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of atorvastatin (ATO; 10 - 80 mg/day), fluvastatin (FLU; 20 - 40 mg/day or 40 mg twice daily), lovastatin (LOV; 20 - 40 mg/day or 40 mg twice daily), pravastatin (PRA; 10 - 40 mg/day) and simvastatin (SIM; 10 - 40 mg/day) for the treatment of hypercholesterolaemia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

2003 NHS Economic Evaluation Database.

82. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes

Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes Schwartz G G, Ganz P, Waters D, Arikian S Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of atorvastatin (80 mg/day), initiated 24 to 96 hours after an acute coronary syndrome (ACS), to prevent death and nonfatal ischaemic events in patients with unstable angina or non-Q wave acute myocardial infarction (MI). Type of intervention Secondary prevention. Economic

2003 NHS Economic Evaluation Database.

83. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study

Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study Early benefit from structured care with atorvastatin in patients (...) with coronary heart disease and diabetes mellitus: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study Athyros V G, Papageorgiou A A, Symeonidis A N, Didangelos T P, Pehlivanidis A N, Bouloukos V I, Mikhailidis D P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2003 NHS Economic Evaluation Database.

84. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis (Abstract)

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD (...) ) in hypertensive patients who are not conventionally deemed dyslipidaemic.Of 19342 hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors) randomised to one of two antihypertensive regimens in the Anglo-Scandinavian Cardiac Outcomes Trial, 10305 with non-fasting total cholesterol concentrations 6.5 mmol/L or less were randomly assigned additional atorvastatin 10 mg or placebo. These patients formed the lipid-lowering arm of the study. We planned follow-up for an average

2003 Lancet Controlled trial quality: predicted high

85. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. (Abstract)

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Patients experience the highest rate of death and recurrent ischemic events during the early period after an acute coronary syndrome, but it is not known whether early initiation of treatment with a statin can reduce the occurrence of these early events.To determine whether treatment with atorvastatin, 80 mg/d, initiated 24 to 96 hours after an acute coronary (...) syndrome, reduces death and nonfatal ischemic events.A randomized, double-blind trial conducted from May 1997 to September 1999, with follow-up through 16 weeks at 122 clinical centers in Europe, North America, South Africa, and Australasia.A total of 3086 adults aged 18 years or older with unstable angina or non-Q-wave acute myocardial infarction.Patients were stratified by center and randomly assigned to receive treatment with atorvastatin (80 mg/d) or matching placebo between 24 and 96 hours after

2001 JAMA Controlled trial quality: predicted high

86. [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia]

[Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Analisis coste-efectividad de atorvastatina frente a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolemicos en atencion primaria [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Analisis coste-efectividad de atorvastatina frente (...) a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolemicos en atencion primaria [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Tarraga Lopez P J, Celada Rodriguez A, Cerdan Oliver M, Solera Albero J, Ocana Lopez J M, de Miguel Clave J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary

2001 NHS Economic Evaluation Database.

87. Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia

Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia (...) elemental calcium) three times per day with meals) plus atorvastatin calcium (10mg once daily) in the reduction of lipoprotein (LDL) in the treatment of dyslipidemia and hyperphosphatemia for patients with chronic renal insufficiency (CRI). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with CRI, but no cardiovascular disease, with moderate hyperphosphatemia (plasma phosphorus 6.0-7.5 mg/dl) and a borderline high

2000 NHS Economic Evaluation Database.

88. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. (Abstract)

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. Percutaneous coronary revascularization is widely used in improving symptoms and exercise performance in patients with ischemic heart disease and stable angina pectoris. In this study, we compared percutaneous coronary revascularization with lipid-lowering treatment for reducing the incidence of ischemic events.We studied 341 patients (...) with stable coronary artery disease, relatively normal left ventricular function, asymptomatic or mild-to-moderate angina, and a serum level of low-density lipoprotein (LDL) cholesterol of at least 115 mg per deciliter (3.0 mmol per liter) who were referred for percutaneous revascularization. We randomly assigned the patients either to receive medical treatment with atorvastatin, at 80 mg per day (164 patients), or to undergo the recommended percutaneous revascularization procedure (angioplasty) followed

1999 NEJM Controlled trial quality: uncertain

89. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias Yee H S, Fong N T Authors' objectives To assess the efficacy and safety of atorvastatin in the treatment of dyslipidemias. Searching MEDLINE (January 1960 to April 1998) and Current Contents were searched for articles published (...) in the English language. Additional references were sought from bibliographies of identified studies and unpublished data from manufacturers. Study selection Study designs of evaluations included in the review The authors selected open and controlled human and animal clinical trials on the pharmacology, pharmacokinetics, therapeutic use and adverse effects of atorvastatin, limited to information on human clinical trials. Randomised clinical trials (RCTs) and open clinical trials that evaluated atorvastatin

1998 DARE.

90. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. (Abstract)

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. To assess the lipid-lowering effect of atorvastatin (a new 3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitor) on levels of serum triglycerides and other lipoprotein fractions in patients with primary hypertriglyceridemia, determine if atorvastatin causes a redistribution of triglycerides in various lipoprotein fractions, and assess its safety by reporting adverse (...) 5 mg, 20 mg, or 80 mg of atorvastatin, or placebo.Percent change from baseline in total triglycerides for three dose levels of atorvastatin compared with placebo.Mean reductions in total triglycerides between 5 mg, 20 mg, and 80 mg of atorvastatin and placebo after 4 weeks of treatment were -26.5%, -32.4%, -45.8%, and -8.9%, respectively. Mean reductions in LDL-C were -16.7%, -33.2%, -41.4%, and -1.4%, respectively, and very low-density lipoprotein cholesterol (VLDL-C) were -34.3%, -45.9%, -57.7

1996 JAMA Controlled trial quality: uncertain